Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
Period EndTotal current assets (Million JPY)YoY (%)
Mar 31, 20253,622-18.83%
Mar 31, 20244,462-4.43%
Mar 31, 20234,669-25.94%
Mar 31, 20226,304-8.67%
Mar 31, 20216,902-12.85%
Mar 31, 20207,920+13.37%
Mar 31, 20196,986+2.11%
Mar 31, 20186,841-45.02%
Mar 31, 201712,442-13.09%
Mar 31, 201614,317+0.76%
Mar 31, 201514,209
AI Chat